GLP‑1 pills vs injections explained

The new wrinkle in weight-loss drugs is that the same hormone signal can now come in two very different packages: a once-daily pill or a once-weekly shot. Both are built to copy glucagon-like peptide-1, a gut hormone your body releases after eating that lowers appetite and slows how fast food leaves the stomach. (yalemedicine.org) That slowdown is the whole trick. If your stomach empties more slowly and your brain keeps getting a “you’ve eaten” signal, many people feel full sooner and stay full longer. (yalemedicine.org) For years, the obesity versions were mostly injections like semaglutide sold as Wegovy and tirzepatide sold as Zepbound. Yale Medicine says the Food and Drug Administration has approved those drugs for adults with a body mass index of 30 or higher, or 27 plus a weight-related condition like high blood pressure, high cholesterol, or sleep apnea. (yalemedicine.org) Now there is a pill version of Wegovy too. The Food and Drug Administration approved oral semaglutide in December 2025, and Novo Nordisk launched it in the United States in January 2026. (ajmc.com, aamc.org) The pill is not just “the shot in tablet form” in a simple sense. A shot goes under the skin once a week, while the pill has to survive the stomach, get absorbed in tiny amounts, and be taken every morning on an empty stomach. (accessdata.fda.gov) That timing rule is stricter than most people expect. The Wegovy tablet label says to take it with no more than 4 ounces of water and then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. (accessdata.fda.gov) The tradeoff is convenience versus routine. A weekly injection asks you to use a needle, but a daily pill asks you to build your morning around it every single day. (wegovy.com, aamc.org) The weight-loss results are close enough that the choice may come down to lifestyle. In the OASIS 4 trial, adults taking oral semaglutide lost 13.6% of body weight on average at 64 weeks, while earlier STEP 1 data for injectable Wegovy showed about 14.9% weight loss at 68 weeks, although those were separate trials and not a head-to-head test. (ajmc.com, nejm.org) Side effects look familiar because the mechanism is familiar. Yale Medicine lists nausea, vomiting, diarrhea, constipation, and stomach pain as common problems, and the Food and Drug Administration label carries a boxed warning about thyroid C-cell tumors seen in rodents. (yalemedicine.org, accessdata.fda.gov) Some people should not start either version without a careful review first. Yale Medicine says pregnancy, a prior history of pancreatitis, and a personal or family history tied to medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are major reasons clinicians pause or avoid these drugs. (yalemedicine.org) The pill is already moving fast. The Association of American Medical Colleges reported that about 170,000 prescriptions were written within three weeks of the January 5, 2026 U.S. launch, and Eli Lilly is also pushing an experimental oral drug called orforglipron through late-stage obesity trials. (aamc.org, thelancet.com) The simplest way to think about it is this: injections are less frequent, pills are more familiar, and both only work well if people can stay on them. Yale Medicine’s advice is to start with a clinician who treats obesity as a chronic disease, because the real job is not picking a format once but managing dose changes, side effects, and long-term follow-up. (yalemedicine.org)